Literature DB >> 24920635

Cannabinoid 1 and transient receptor potential vanilloid 1 receptors discretely modulate evoked glutamate separately from spontaneous glutamate transmission.

Jessica A Fawley1, Mackenzie E Hofmann2, Michael C Andresen2.   

Abstract

Action potentials trigger synaptic terminals to synchronously release vesicles, but some vesicles release spontaneously. G-protein-coupled receptors (GPCRs) can modulate both of these processes. At cranial primary afferent terminals, the GPCR cannabinoid 1 (CB1) is often coexpressed with transient receptor potential vanilloid 1 (TRPV1), a nonselective cation channel present on most afferents. Here we tested whether CB1 activation modulates synchronous, action potential-evoked (eEPSCs) and/or spontaneous (sEPSCs) EPSCs at solitary tract nucleus neurons. In rat horizontal brainstem slices, activation of solitary tract (ST) primary afferents generated ST-eEPSCs that were rapidly and reversibly inhibited from most afferents by activation of CB1 with arachidonyl-2'-chloroethylamide (ACEA) or WIN 55,212-2 [R-(+)-(2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl)(1-naphthalenyl) methanone monomethanesulfonate]. The CB1 antagonist/inverse agonist AM251 [N-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide] blocked these responses. Despite profound depression of ST-eEPSCs during CB1 activation, sEPSCs in these same neurons were unaltered. Changes in temperature changed sEPSC frequency only from TRPV1(+) afferents (i.e., thermal sEPSC responses only occurred in TRPV1(+) afferents). CB1 activation failed to alter these thermal sEPSC responses. However, the endogenous arachidonate metabolite N-arachidonyldopamine (NADA) promiscuously activated both CB1 and TRPV1 receptors. NADA inhibited ST-eEPSCs while simultaneously increasing sEPSC frequency, and thermally triggered sEPSC increases in neurons with TRPV1(+) afferents. We found no evidence for CB1/TRPV1 interactions suggesting independent regulation of two separate vesicle pools. Together, these data demonstrate that action potential-evoked synchronous glutamate release is modulated separately from TRPV1-mediated glutamate release despite coexistence in the same central terminations. This two-pool arrangement allows independent and opposite modulation of glutamate release by single lipid metabolites.
Copyright © 2014 the authors 0270-6474/14/348324-09$15.00/0.

Entities:  

Keywords:  CB1; NADA; NTS; TRPV1; vesicle pool

Mesh:

Substances:

Year:  2014        PMID: 24920635      PMCID: PMC4051980          DOI: 10.1523/JNEUROSCI.0315-14.2014

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  56 in total

Review 1.  The vanilloid receptor: a molecular gateway to the pain pathway.

Authors:  M J Caterina; D Julius
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

2.  Reliability of monosynaptic sensory transmission in brain stem neurons in vitro.

Authors:  M W Doyle; M C Andresen
Journal:  J Neurophysiol       Date:  2001-05       Impact factor: 2.714

3.  Quantal mechanism of neural transmitter release.

Authors:  B Katz
Journal:  Science       Date:  1971-07-09       Impact factor: 47.728

4.  Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors.

Authors:  Silvia Marinelli; Vincenzo Di Marzo; Nicola Berretta; Isabel Matias; Mauro Maccarrone; Giorgio Bernardi; Nicola B Mercuri
Journal:  J Neurosci       Date:  2003-04-15       Impact factor: 6.167

5.  Vanilloid receptors presynaptically modulate cranial visceral afferent synaptic transmission in nucleus tractus solitarius.

Authors:  Mark W Doyle; Timothy W Bailey; Young-Ho Jin; Michael C Andresen
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

6.  Endocannabinoids inhibit transmission at granule cell to Purkinje cell synapses by modulating three types of presynaptic calcium channels.

Authors:  Solange P Brown; Patrick K Safo; Wade G Regehr
Journal:  J Neurosci       Date:  2004-06-16       Impact factor: 6.167

7.  An immuno-electronmicroscopical study comparing vasopressin, oxytocin, substance P and enkephalin containing nerve terminals in the nucleus of the solitary tract of the rat.

Authors:  P Voorn; R M Buijs
Journal:  Brain Res       Date:  1983-06-27       Impact factor: 3.252

8.  Purinergic and vanilloid receptor activation releases glutamate from separate cranial afferent terminals in nucleus tractus solitarius.

Authors:  Young-Ho Jin; Timothy W Bailey; Bai-Yan Li; John H Schild; Michael C Andresen
Journal:  J Neurosci       Date:  2004-05-19       Impact factor: 6.167

9.  Delta9-tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets.

Authors:  Marja D Van Sickle; Lorraine D Oland; Ken Mackie; Joseph S Davison; Keith A Sharkey
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2003-06-04       Impact factor: 4.052

10.  An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors.

Authors:  Susan M Huang; Tiziana Bisogno; Marcello Trevisani; Abdulmonem Al-Hayani; Luciano De Petrocellis; Filomena Fezza; Michele Tognetto; Timothy J Petros; Jocelyn F Krey; Constance J Chu; Jeffrey D Miller; Stephen N Davies; Pierangelo Geppetti; J Michael Walker; Vincenzo Di Marzo
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

View more
  28 in total

1.  Vanilloids selectively sensitize thermal glutamate release from TRPV1 expressing solitary tract afferents.

Authors:  Mackenzie E Hofmann; Michael C Andresen
Journal:  Neuropharmacology       Date:  2015-10-22       Impact factor: 5.250

2.  Novel Ca2+-dependent mechanisms regulate spontaneous release at excitatory synapses onto CA1 pyramidal cells.

Authors:  Walter E Babiec; Thomas J O'Dell
Journal:  J Neurophysiol       Date:  2017-11-15       Impact factor: 2.714

Review 3.  Molecular underpinnings of synaptic vesicle pool heterogeneity.

Authors:  Devon C Crawford; Ege T Kavalali
Journal:  Traffic       Date:  2015-04       Impact factor: 6.215

4.  Identification of N-arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors.

Authors:  William J Redmond; Erin E Cawston; Natasha L Grimsey; Jordyn Stuart; Amelia R Edington; Michelle Glass; Mark Connor
Journal:  Br J Pharmacol       Date:  2015-11-17       Impact factor: 8.739

5.  Activation of TRPV1 in nucleus tractus solitarius reduces brown adipose tissue thermogenesis, arterial pressure, and heart rate.

Authors:  Mazher Mohammed; Christopher J Madden; Michael C Andresen; Shaun F Morrison
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-03-28       Impact factor: 3.619

6.  External QX-314 inhibits evoked cranial primary afferent synaptic transmission independent of TRPV1.

Authors:  Mackenzie E Hofmann; Tally M Largent-Milnes; Jessica A Fawley; Michael C Andresen
Journal:  J Neurophysiol       Date:  2014-09-03       Impact factor: 2.714

7.  Activation of astrocytic PAR1 receptors in the rat nucleus of the solitary tract regulates breathing through modulation of presynaptic TRPV1.

Authors:  Rafiq Huda; Zheng Chang; Jeehaeh Do; Donald R McCrimmon; Marco Martina
Journal:  J Physiol       Date:  2018-01-15       Impact factor: 5.182

8.  Excitatory amino acid transporters tonically restrain nTS synaptic and neuronal activity to modulate cardiorespiratory function.

Authors:  Michael P Matott; Brian C Ruyle; Eileen M Hasser; David D Kline
Journal:  J Neurophysiol       Date:  2015-12-30       Impact factor: 2.714

9.  5-HT3R-sourced calcium enhances glutamate release from a distinct vesicle pool.

Authors:  Jessica A Fawley; Mark W Doyle; Michael C Andresen
Journal:  Brain Res       Date:  2019-07-23       Impact factor: 3.252

Review 10.  Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention.

Authors:  F Markus Leweke; Juliane K Mueller; Bettina Lange; Stefan Fritze; Cristina E Topor; Dagmar Koethe; Cathrin Rohleder
Journal:  CNS Drugs       Date:  2018-07       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.